Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.

McDuff SGR, Dietrich J, Atkins KM, Oh KS, Loeffler JS, Shih HA.

Cancer Med. 2020 Jan;9(1):3-11. doi: 10.1002/cam4.2686. Epub 2019 Nov 7. Review.

2.

Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review.

Hafazalla K, Sahgal A, Jaja B, Perry JR, Das S.

Oncotarget. 2018 Sep 14;9(72):33623-33633. doi: 10.18632/oncotarget.25890. eCollection 2018 Sep 14.

3.

Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.

Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, Chicoine MR, Dacey RG, Rich KM, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):268-76. doi: 10.1016/j.ijrobp.2014.10.027.

PMID:
25636755
4.

Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.

Lecavalier-Barsoum M, Quon H, Abdulkarim B.

Cochrane Database Syst Rev. 2014 May 15;(5):CD007104. doi: 10.1002/14651858.CD007104.pub2. Review.

PMID:
24833028
5.

Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.

Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D.

J Neurooncol. 2015 Sep;124(2):197-205. doi: 10.1007/s11060-015-1822-1. Epub 2015 Jun 2.

PMID:
26033545
6.

The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.

Ziu M, Kalkanis SN, Gilbert M, Ryken TC, Olson JJ.

J Neurooncol. 2015 Dec;125(3):585-607. doi: 10.1007/s11060-015-1931-x. Epub 2015 Nov 3. Review.

PMID:
26530261
7.

Low-grade and anaplastic oligodendroglioma.

Van Den Bent MJ, Bromberg JE, Buckner J.

Handb Clin Neurol. 2016;134:361-80. doi: 10.1016/B978-0-12-802997-8.00022-0. Review.

PMID:
26948366
8.

To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment.

Paľa A, Coburger J, Scherer M, Ahmeti H, Roder C, Gessler F, Jungk C, Scheuerle A, Senft C, Tatagiba M, Synowitz M, Wirtz CR, Schmitz B, Unterberg AW.

J Neurosurg. 2019 Jul 19:1-8. doi: 10.3171/2019.4.JNS183395. [Epub ahead of print]

PMID:
31323633
9.

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K.

J Clin Oncol. 2013 Jan 20;31(3):344-50. doi: 10.1200/JCO.2012.43.2229. Epub 2012 Oct 15.

PMID:
23071237
10.

Procarbazine, lomustine and vincristine for recurrent high-grade glioma.

Parasramka S, Talari G, Rosenfeld M, Guo J, Villano JL.

Cochrane Database Syst Rev. 2017 Jul 26;7:CD011773. doi: 10.1002/14651858.CD011773.pub2. Review.

11.

Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.

Izquierdo C, Alentorn A, Idbaih A, Simó M, Kaloshi G, Ricard D, Barritault M, Meyronet D, Bruna J, Honnorat J, Delattre JY, Ducray F.

J Neurooncol. 2018 Feb;136(3):533-539. doi: 10.1007/s11060-017-2677-4. Epub 2017 Nov 15.

PMID:
29143276
12.

Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Nahed BV, Redjal N, Brat DJ, Chi AS, Oh K, Batchelor TT, Ryken TC, Kalkanis SN, Olson JJ.

J Neurooncol. 2015 Dec;125(3):609-30. doi: 10.1007/s11060-015-1910-2. Epub 2015 Nov 3. Review.

PMID:
26530264
13.

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.

Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME.

Acta Neuropathol. 2018 Apr;135(4):601-615. doi: 10.1007/s00401-018-1810-6. Epub 2018 Jan 24.

14.

11C-Methionine Integrated PET/MRI-Based Texture Analysis Features May Have a Potential Ability to Distinguish Oligodendroglioma (IDH-Mutant and 1p/19q-Codeleted) From Varied Gliomas.

Zhao K, Yu P, Xue Z, Liu J, Yao A, Zhao Y, Yang F, Tian J, Xu B.

Acad Radiol. 2019 Oct 10. pii: S1076-6332(19)30446-5. doi: 10.1016/j.acra.2019.09.013. [Epub ahead of print]

PMID:
31607471
15.

Treatment of anaplastic glioma.

Wick W, Wiestler B, Platten M.

Cancer Treat Res. 2015;163:89-101. doi: 10.1007/978-3-319-12048-5_6. Review.

PMID:
25468227
16.

MRI radiomics analysis of molecular alterations in low-grade gliomas.

Shofty B, Artzi M, Ben Bashat D, Liberman G, Haim O, Kashanian A, Bokstein F, Blumenthal DT, Ram Z, Shahar T.

Int J Comput Assist Radiol Surg. 2018 Apr;13(4):563-571. doi: 10.1007/s11548-017-1691-5. Epub 2017 Dec 21.

PMID:
29270916
17.

Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.

Rudà R, Pellerino A, Pace A, Carapella CM, Dealis C, Caroli M, Faedi M, Bello L, Migliore E, Marchese G, Bertero L, Cassoni P, Soffietti R.

J Neurooncol. 2019 Oct;145(1):115-123. doi: 10.1007/s11060-019-03277-x. Epub 2019 Sep 25. Erratum in: J Neurooncol. 2019 Dec;145(3):593.

PMID:
31556015
18.
19.

Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.

Anderson MD, Gilbert MR.

Oncology (Williston Park). 2013 Apr;27(4):315-20, 322. Review.

20.

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.

Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D; POLA Network .

Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.

PMID:
31832685

Supplemental Content

Support Center